(VIANEWS) – SCYNEXIS (SCYX), Consolidated Water Co. Ltd. (CWCO), Insulet (PODD) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SCYNEXIS (SCYX)
884.1% sales growth and 132.23% return on equity
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Earnings Per Share
As for profitability, SCYNEXIS has a trailing twelve months EPS of $1.49.
PE Ratio
SCYNEXIS has a trailing twelve months price to earnings ratio of 1.09. Meaning, the purchaser of the share is investing $1.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 132.23%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 45.9% and 98.6%, respectively.
Yearly Top and Bottom Value
SCYNEXIS’s stock is valued at $1.62 at 14:22 EST, way below its 52-week high of $3.87 and way higher than its 52-week low of $1.15.
Sales Growth
SCYNEXIS’s sales growth is negative 10.1% for the ongoing quarter and 884.1% for the next.
2. Consolidated Water Co. Ltd. (CWCO)
48.7% sales growth and 13.56% return on equity
Consolidated Water Co. Ltd., together with its subsidiaries, designs, constructs, manages, and operates water production and water treatment plants primarily in the Cayman Islands, the Bahamas, and the United States. The company operates through four segments: Retail, Bulk, Services, and Manufacturing. It uses reverse osmosis technology to produce potable water from seawater. The company produces and supplies water to end-users, including residential, commercial, and government customers, as well as government-owned distributors. It also provides design, engineering, construction, procurement, and management services for desalination projects and water treatment plants, as well as management and engineering services relating to municipal water distribution and treatment. In addition, the company manufactures and services a range of water-related products, including reverse osmosis desalination equipment, membrane separation equipment, filtration equipment, piping systems, vessels, and custom fabricated components; and provides design, engineering, consulting, management, inspection, training, and equipment maintenance services for commercial, municipal, and industrial water production, supply, and treatment, as well as desalination and wastewater treatment. Consolidated Water Co. Ltd. was incorporated in 1973 and is headquartered in Grand Cayman, the Cayman Islands.
Earnings Per Share
As for profitability, Consolidated Water Co. Ltd. has a trailing twelve months EPS of $1.44.
PE Ratio
Consolidated Water Co. Ltd. has a trailing twelve months price to earnings ratio of 23.97. Meaning, the purchaser of the share is investing $23.97 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.56%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 99%, now sitting on 155.39M for the twelve trailing months.
Moving Average
Consolidated Water Co. Ltd.’s value is way above its 50-day moving average of $30.40 and way higher than its 200-day moving average of $22.16.
Sales Growth
Consolidated Water Co. Ltd.’s sales growth is 59.2% for the present quarter and 48.7% for the next.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Sep 28, 2023, the estimated forward annual dividend rate is 0.35 and the estimated forward annual dividend yield is 1.01%.
3. Insulet (PODD)
23.6% sales growth and 23.18% return on equity
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Earnings Per Share
As for profitability, Insulet has a trailing twelve months EPS of $1.73.
PE Ratio
Insulet has a trailing twelve months price to earnings ratio of 108.67. Meaning, the purchaser of the share is investing $108.67 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.18%.
4. Gilat Satellite Networks Ltd. (GILT)
10.1% sales growth and 5.46% return on equity
Gilat Satellite Networks Ltd., together with its subsidiaries, provides satellite-based broadband communication solutions in Israel and internationally. It operates through Fixed Networks, Mobility Solutions, and Terrestrial Infrastructure Projects segments. The company designs and manufactures ground-based satellite communications equipment; and provides solutions and end-to-end services. Its portfolio consists of very small aperture terminals, amplifiers, modems, on-the-move antennas, solid state power amplifiers, block upconverters, transceivers, low-profile antennas, and on-the-move/on-the-pause terminals and modems. The company also offers turnkey integrated solutions, including managed satellite network services, network planning and optimization, satellite capacity, remote network operation, call center support, hub and field operations, and communication networks construction and installation services. In addition, it provides connectivity services, Internet access, and telephony services to enterprise, government, and residential customers; and builds telecommunication infrastructure using fiber-optic and wireless technologies for broadband connectivity. The company sells its products and solutions to communication service providers, satellite operators, governments, mobile network operators, telecommunication companies, and system integrators, as well as to defense and homeland security organizations, and directly to end-users. Gilat Satellite Networks Ltd. was incorporated in 1987 and is headquartered in Petah Tikva, Israel.
Earnings Per Share
As for profitability, Gilat Satellite Networks Ltd. has a trailing twelve months EPS of $0.24.
PE Ratio
Gilat Satellite Networks Ltd. has a trailing twelve months price to earnings ratio of 26.25. Meaning, the purchaser of the share is investing $26.25 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.46%.
5. IDEXX Laboratories (IDXX)
8.1% sales growth and 92.79% return on equity
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; OPTI SARS-CoV-2 RT-PCR test kit for human COVID-19 testing; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Earnings Per Share
As for profitability, IDEXX Laboratories has a trailing twelve months EPS of $9.8.
PE Ratio
IDEXX Laboratories has a trailing twelve months price to earnings ratio of 48.83. Meaning, the purchaser of the share is investing $48.83 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 92.79%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
IDEXX Laboratories’s EBITDA is 11.29.
Yearly Top and Bottom Value
IDEXX Laboratories’s stock is valued at $478.54 at 14:22 EST, way below its 52-week high of $564.74 and way higher than its 52-week low of $372.50.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.8%, now sitting on 3.59B for the twelve trailing months.
6. Carrols Restaurant Group (TAST)
7.9% sales growth and 5.3% return on equity
Carrols Restaurant Group, Inc., through its subsidiaries, operates as a restaurant company in the United States. The company operates as a Burger King franchisee. As of January 3, 2021, it operated 1,009 Burger King restaurants located in 23 Northeastern, Midwestern, Southcentral, and Southeastern states; and 65 Popeyes restaurants in seven Southeastern states. The company was founded in 1960 and is headquartered in Syracuse, New York.
Earnings Per Share
As for profitability, Carrols Restaurant Group has a trailing twelve months EPS of $0.06.
PE Ratio
Carrols Restaurant Group has a trailing twelve months price to earnings ratio of 126.17. Meaning, the purchaser of the share is investing $126.17 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.3%.
